OBJECTIVE: To investigate the effects of different treatments on the prognosis of patients with non-Hodgkin's lymphomas of the nasal cavity. METHODS: A retrospective study of 59 patients who suffered from stage I(E) primary non-Hodgkin's lymphomas of the nasal cavity was presented. They were treated by radiotherapy and chemotherapy of CHOP regimen, in which 33 patients received chemotherapy plus radiotherapy, 8 patients received radiotherapy plus chemotherapy, 10 patients received chemotherapy alone, and 8 patients received radiotherapy alone. Survival analysis was performed by Kaplan-Meier method, the difference between groups was evaluated by log-rank test, and the comparison of rates was carried out by chi(2) test. RESULTS: The overall 1-, 3- and 5-year survival rates were 71.2%, 42.0% and 38.5%, respectively. There was no significant difference among the patients received different treatments (chi(2) = 2.98, P = 0.3943), but the patients received radiotherapy plus chemotherapy seemed to have a better survival curve than other patients. The 1-, 3- and 5-year survival rates were 84.2%, 67.7% and 62.0% for lesion limited in nasal cavity but 50.0%, 14.3% and 14.3% for lesion extended and involved the adjacent structures (chi(2) = 10.46, P = 0.0012). As the initial therapy, 24 patients who received chemotherapy of more than 3 cycles, and 16 patients who received radiotherapy of more than 40 Gy, and the complete response (CR) rates were 25.0% and 75.0% (chi(2) = 9.697, P = 0.002). Among 43 patients received chemotherapy, the CR rates for those who received 2, 3 - 4 and 5 - 6 cycles were 10.5%, 25.0% and 25.0%, respectively (chi(2) = 1.467, P = 0.48). Patients who received chemotherapy plus radiotherapy have higher rates of both complication and treatment-related mortality, but the difference was not statistically significant (P = 0.202 and 0.693). CONCLUSION: For stage I non-Hodgkin's lymphomas of the nasal cavity, radiotherapy should be the first treatment to get early local control. Chemotherapy may be followed at the discretion of the pathological grade and clinical staging, or IPI.
Key words:
Nasal neoplasm/drug therapy; Nasal neoplasm/ radiotherapy; Lymphoma, non-Hodgkin/drug therapy; Lymphoma, non-Hodgkin/radiotherapy; Comprehensive treatment; Prognosis
In the title centrosymmetric mononuclear cobalt(II) compound, [Co(NCS)2(C19H15N5O)2], the central CoII atom is coordinated by four N atoms from two 4-(4-methoxyphenyl)-3,5-di-2-pyridyl-4H-1,2,4-triazole ligands and two N atoms from two thiocyanate counter-ions. The coordination geometry is slightly distorted octahedral.
Objective
To observe the effect of long-term intensive glucose control therapy on diabetic retinopathy in outpatients with type 2 diabetes mellitus.
Methods
Forty-nine patients with type 2 diabetes mellitus were randomly assigned to participate in the trial from 2002 to 2007, receiving either intensive (24 cases) or standard glucose control (25 cases). The patients were examined by the same ophthalmologists to identify any new diabetic retinopathy (DR). After 5 years of intensive glucose control, all of the patients were asked to attend our clinic every 6 months, but no attempts were made to maintain their previously assigned therapies. Hemoglobin A1c (HbA1c) was measured regularly. In November of 2009, a retinal examination was carried out by the same ophthalmologist who worked in the trial. The visual acuity, lens, vitreous body and fundus were examined after pupil dilation to identify diabetic retinopathy (DR). Fundus fluorescein angiography and retinal laser photocoagulation were carried out when necessary.
Results
In the second year after enrollment in the trail, the median HbA1c level of the intensive-therapy group was significantly lower than that of the standard-therapy group [(6.3±0.6)% vs. (7.2±1.2)%, t=2.09, P<0.05], and was maintained in a controlled level throughout the following 4 years. During the post-trial monitoring, no new case of of macula edema or diabetic associated blindness occurred in either intensive or standard-therapy group, the whole occurrence of micro-aneurysms, fundus hemorrhage, as well as those who needed retinal laser photocoagnlation and lowering in visual acuity in intensive-therapy group was lower than that in the standard-therapy group (3 vs. 14 1 vs. 7, 2 vs. 4, 3 vs. 11, respectively; 9 vs. 36, totally, χ2=4.719, P<0.05). During the first post-trial monitoring, there was no difference in median HbA1c level between intensive-therapy group and standard-therapy group [(7.2±1.1)% vs. (7.3±1.3)%, t=0.25, P=0.806], which was sustained in the following years. In the trail, no new case of fundus hemorrhage or diabetic associated blindness occurred in intensive-therapy group during the five-year period of therapy. Number of new episodes of micro-aneurysm, macula edema were less in intensive-therapy group than that in standard-therapy group, number of new episodes of lowering in visual acuity, and those who needed retinal laser photocoagnlation, were significantly less in intensive-therapy group than that in standard-therapy group(15 vs. 25, 4 vs. 23, Z=-4.459, P<0.05) during five-year follow-up.
Conclusions
The benefit of reduced incidence of diabetic retinopathy in intensive glucose can be maintained because of the legacy effect.
Key words:
Diabetes mellitus, type 2; Intensive glucose control; Diabetic retinopathy
Objective: To investigate the ultrasonographic features of breast cancer, and analyse its correlation with ER, PR, HER-2 and nm23.
Methods: Female patients with breast cancer from January 2015 to December 2016 were selected and retrospectively analysed ultrasound imaging performance in accordance with the inclusion criteria. And immunohistochemical method was used to detect the expression of ER, PR, HER-2 and nm23 in pathological specimens to analyse its correlation with ultrasonic imaging features.
Results: The positive rate of ER, PR in patients with spiculation in the lumps’ edge was significantly higher than that of patients with no spiculation in the lumps’ edge (P 1 in the lumps was greater than that of patients with aspect ratio ≤ 1 (P<0.05). Whether the lesion of breast cancer had rear echo increased or not had no significant relationship with the positive rate of ER, PR, HER-2 and nm23.
Conclusion: There is correlation between ultrasonic performance in breast cancer and the expression of ER, PR, HER-2 and nm23, and through the features of ultrasound, the expression of ER, PR, HER-2 and nm23 in lesion of tumor can be partly estimated.
A novel mononuclear platinum(ii) anticancer complex of danysl bis(2-benzothiazolylmethyl)amine with a dimethyl sulfoxide as a leaving group was reported.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)